Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc. engages in the provision of cell engineering therapies. It is involved in the development of mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. The company was founded in 1984 and is headquartered in Cambridge, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK, Aug. 20, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today provided highlights from a Shareholder Update Call conducted by President and Chief Executive Officer Howard J. Federoff, M.D., Ph.D. on August 19, 2021.

Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder Update Call from August 19, 2021

BROOKLYN, N.Y., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced that it will host a shareholder update conference call on Thursday, August 19, 2021, at 4:30 p.m. ET.

Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call on Thursday, August 19, 2021 at 4:30 PM ET

NEW YORK, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that gene editing/cell and cytokine therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced financial results for the quarter ended June 30, 2021.

Brooklyn ImmunoTherapeutics Announces Second Quarter 2021 Financial Results

NEW YORK, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced that Chief Executive Officer Howard J. Federoff, M.D., Ph.D., will present a corporate overview at the SNN Virtual Investor Conference being held August 17 – 19, 2021.

Brooklyn ImmunoTherapeutics to Present at the SNN Virtual Investor Conference on August 18, 2021

BROOKLYN, N.Y., July 23, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced that on July 15, 2021, Jay Sial was granted a non-qualified stock option covering 71,000 shares of Brooklyn's common stock (the “Time-Based Option”) and a restricted stock unit covering 35,700 shares of Brooklyn's common stock (the “RSU”).

Brooklyn Immuno Reports Inducement Grants

Acquisition Advances Transformation Into Platform Company Focused on Cell, Gene Editing and Cytokine Therapy

Brooklyn ImmunoTherapeutics Completes Acquisition of Novellus Therapeutics

NEW YORK, July 13, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced the appointment of Jay Sial as its Chief Administrative Officer, effective July 15, 2021.

Brooklyn ImmunoTherapeutics Welcomes Jay Sial as Chief Administrative Officer

NEW YORK, July 12, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics LLC (NYSE American: BTX) (“Brooklyn” or “the Company”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced that Chief Executive Officer Howard J. Federoff, M.D., Ph.D., will present a corporate overview at the Access to Giving Virtual Investor Conference being held July 13 – 15, 2021.

Brooklyn ImmunoTherapeutics to Present at the Access to Giving Virtual Investor Conference on July 15, 2021

Annovis Bio

Citius Pharmaceuticals

Jazz Pharmaceuticals

Mind Medicine MindMed

Cassava Sciences Inc

SpringWorks Therapeutics Inc

Pharma stocks like MNMD stock and ANVS stock offer investors long-term growth potential in a market on track to hit a value of $1.70 trillion. The post 7 Top-Rated Pharmaceutical Companies to Invest In for July appeared first on InvestorPlace.

7 Top-Rated Pharmaceutical Companies to Invest In for July

Ashford Hospitality Trust

GEO Group

Pubmatic

Skillz

SNDL Inc.

Wish

Looking to roll the dice? Consider buying one (or more) of these seven high-risk, but possibly high-return, Reddit stocks.

7 Best Reddit Stocks to Buy If You Have $100 to Spare

The biotech is bulking up with a new acquisition.

Why Brooklyn ImmunoTherapeutics Crushed the Market Today

Brooklyn ImmunoTherapeutics LLC (NYSE: BTX) has executed a non-binding letter of intent to acquire Novellus Therapeutics, a company developing engineered mesenchymal stem cell (MSC) therapies using mRNA cell reprogramming and gene editing technologies licensed from Factor Bioscience. Under the terms of the LOI, the parties intend to sign a definitive agreement and work to close the acquisition by July 15.

Brooklyn ImmunoTherapeutics Stock Rises After Novellus Therapeutics Buyout Deal

Novellus Therapeutics develops next-generation mesenchymal stem cell products using licensed patented mRNA cell reprogramming and gene editing technologies Novellus Therapeutics develops next-generation mesenchymal stem cell products using licensed patented mRNA cell reprogramming and gene editing technologies

Brooklyn ImmunoTherapeutics Executes Letter of Intent to Acquire Novellus Therapeutics

BROOKLYN, N.Y., June 09, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic disorders, today announced Brooklyn's addition to the Russell 3000 Index. This milestone will take place at the conclusion of the 2021 Russell Indexes' annual reconstitution, effective after the U.S. market opens on June 28, 2021 according to a preliminary list of additions posted June 4, 2021.

Brooklyn ImmunoTherapeutics Set to Join Russell 3000 Index

BROOKLYN, N.Y., June 08, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic disorders, today announced the appointment of Kevin A. D'Amour, Ph.D. as its Chief Scientific Officer.

Brooklyn ImmunoTherapeutics Welcomes Dr. Kevin A. D'Amour as Chief Scientific Officer

BTX stock holders will certainly want to brace for volatility. Still, the outlook's bullish as the company pursues its game-changing research.

Brooklyn Immunotherapeutics Stock Is a Worthy Bet on Genetics Research

BROOKLYN, N.Y.--(BUSINESS WIRE)--Brooklyn ImmunoTherapeutics CEO Howard J. Federoff Provides Roadmap for the Company's Future During May 25, 2021 Shareholder Update Call

Brooklyn ImmunoTherapeutics CEO Howard J. Federoff Provides Roadmap for the Company's Future During May 25, 2021 Shareholder Update Call

The stock price of Brooklyn Immunotherapeutics Inc (NYSEAMERICAN: BTX) increased by 21.02% today. This is why it happened.

BTX Stock Price: 21.02% Increase Explanation

BROOKLYN, N.Y.--(BUSINESS WIRE)--Brooklyn ImmunoTherapeutics Strengthens Investment in Licensed mRNA Technology Platform with $20M Financing

Brooklyn ImmunoTherapeutics Strengthens Investment in Licensed mRNA Technology Platform with $20M Financing

BROOKLYN, N.Y.--(BUSINESS WIRE)--Michael Andreeff, M.D., Ph.D to Join the Scientific Advisory Board of Brooklyn ImmunoTherapeutics, Inc.

Michael Andreeff, M.D., Ph.D to Join the Scientific Advisory Board of Brooklyn ImmunoTherapeutics, Inc.

Is change at the C-suite level a good thing for a company? The facts seem to indicate that it's a positive development for BTX stock holders.

New CEO and Exclusive License Will Bolster Brooklyn Immunotherapeutics

BROOKLYN, N.Y.--(BUSINESS WIRE)--Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call Tuesday May 25, 2021 at 4:30 PM ET

Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call Tuesday May 25, 2021 at 4:30 PM ET

BROOKLYN, N.Y.--(BUSINESS WIRE)--Brooklyn ImmunoTherapeutics announces the appointment of Christopher Rohde, Ph.D. to the Company's Scientific Advisory Board

Christopher Rohde, Ph.D. to Join Scientific Advisory Board of Brooklyn ImmunoTherapeutics, Inc.

Brooklyn ImmunoTherapeutics Inc (NYSE: BTX) has announced a publication in Breast Cancer Research, which demonstrates how multiplex immunofluorescence (mIF) may be used to characterize the immunological activity of IRX-2 in early-stage breast cancer. IRX-2 is an allogeneic, cell-derived biologic with multiple active cytokine components, including IL-2, that act on various parts of the immune system associated with activation of the entire tumor microenvironment.

Publication In Breast Cancer Research Indicate Brooklyn ImmunoTherapeutics' IRX-2 May Hold Promise In Early-Stage Breast Cancer

BROOKLYN, N.Y.--(BUSINESS WIRE)--Brooklyn ImmunoTherapeutics Announces Publication of Results of IRX-2 Monotherapy in Early Stage Breast Cancer in Breast Cancer Research

News for Brooklyn ImmunoTherapeutics Stock (BTX)